Related Experiment Videos
Methodologic guidelines for the design of high-dose chemotherapy regimens
K Margolin1, T Synold, J Longmate
1Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California USA. kmargolin@coh.org
Summary
Phase I high-dose chemotherapy (HDCT) studies show varied methods in design and analysis. New guidelines are proposed to improve these trials, incorporating pharmacology, toxicity assessment, and statistical design for better outcomes.
Area of Science:
- Oncology
- Clinical Pharmacology
- Biostatistics
Background:
- Phase I dose-escalation studies are crucial for determining safe and effective high-dose chemotherapy (HDCT) regimens.
- Existing HDCT Phase I trials exhibit heterogeneity in research methods, impacting their utility for subsequent studies.
Purpose of the Study:
- To review research methods in Phase I HDCT dose-escalation studies.
- To propose new guidelines for HDCT Phase I studies integrating pharmacology, toxicity assessment, statistical design, and long-term follow-up.
Main Methods:
- Literature review of peer-reviewed reports on HDCT dose-escalation studies.
- Analysis of dose escalation techniques, toxicity grading, and pharmacologic correlates.
- Evaluation of methods for defining dose-limiting toxicities and selecting maximum tolerated dose.
Main Results:
- Thirty-five reports were reviewed, revealing heterogeneity in dose escalation, toxicity grading, and statistical methods.
- Variations were observed in defining dose-limiting toxicities and selecting doses for Phase II trials.
- Pharmacologic analyses were infrequent and varied in scope.
Conclusions:
- Heterogeneous methods in Phase I HDCT trials limit their application and impact subsequent research.
- Correlative pharmacologic analyses are underutilized in Phase I HDCT studies.
- Proposed guidelines emphasize a strong pharmacologic basis, analytical pharmacology integration, clear toxicity definitions, and robust statistical input.